A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

NCT01216072 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1053

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Forms of Multiple Sclerosis

Interventions

DRUG: Fingolimod
DRUG: Standard MS DMTs

Sponsor

Novartis Pharmaceuticals